Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases
- PMID: 29168583
- DOI: 10.1002/mds.27252
Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases
Abstract
Background: In addition to Lewy body pathology, amyloid-β plaques and neurofibrillary tangles that are characteristic for Alzheimer's disease are also frequently found in Lewy body diseases.
Objectives: The objective of this study was to investigate tau accumulation patterns in dementia with Lewy bodies and other Lewy body diseases using in vivo 18 F-AV-1451 PET.
Methods: The study included 12 Parkinson's disease (PD) patients with normal cognition, 22 PD patients with cognitive impairment, and 18 dementia with Lewy bodies patients. In addition, 25 Alzheimer's disease patients and 25 healthy controls were included for comparison. All participants underwent 18 F-AV-1451 and 18 F-florbetaben PET scans, and cortical binding values were compared between the controls and each disease group.
Results: When compared with the controls, dementia with Lewy bodies patients showed slightly increased 18 F-AV-1451 binding in the primary sensorimotor and visual cortices and the parieto-temporal cortices, which failed to survive multiple comparisons. Amyloid-positive dementia with Lewy bodies patients showed significantly increased binding in the same regions when compared with controls, and even greater binding in the primary sensorimotor and visual cortices than Alzheimer's disease. Meanwhile, binding in the lateral and medial temporal cortices was less prominent than in Alzheimer's disease. In dementia with Lewy bodies, 18 F-AV-1451 binding in the occipital cortex correlated with 18 F-florbetaben binding. Amyloid-negative patients with normal cognition, patients with cognitive impairment, and dementia with Lewy bodies patients did not show increased 18 F-AV-1451 binding.
Conclusions: Dementia with Lewy bodies patients may harbor 18 F-AV-1451 binding patterns distinct from Alzheimer's disease, with greater involvement of the primary cortices and less involvement of the temporal cortex. Tau burden increases in the Lewy body disease spectrum, and amyloid may play an important role in the accumulation of neocortical tau in Lewy body diseases. © 2017 International Parkinson and Movement Disorder Society.
Keywords: 18F-AV-1451; tau; positron emission tomography; Lewy body disease; dementia with Lewy bodies.
© 2017 International Parkinson and Movement Disorder Society.
Similar articles
-
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.JAMA Neurol. 2016 Nov 1;73(11):1334-1341. doi: 10.1001/jamaneurol.2016.3338. JAMA Neurol. 2016. PMID: 27654968 Free PMC article.
-
AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.Ann Neurol. 2017 Jan;81(1):58-67. doi: 10.1002/ana.24825. Epub 2016 Dec 19. Ann Neurol. 2017. PMID: 27863444 Free PMC article.
-
18 F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy.Mov Disord. 2019 Mar;34(3):344-352. doi: 10.1002/mds.27603. Epub 2019 Jan 7. Mov Disord. 2019. PMID: 30615804 Free PMC article.
-
Molecular imaging of dementia.Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Psychogeriatrics. 2012. PMID: 22712644 Review.
-
Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.Curr Opin Neurol. 2014 Aug;27(4):398-404. doi: 10.1097/WCO.0000000000000107. Curr Opin Neurol. 2014. PMID: 24978635 Review.
Cited by
-
Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia.JAMA Netw Open. 2019 Dec 2;2(12):e1916439. doi: 10.1001/jamanetworkopen.2019.16439. JAMA Netw Open. 2019. PMID: 31790563 Free PMC article.
-
Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis.Front Neurol. 2023 Apr 27;14:1145939. doi: 10.3389/fneur.2023.1145939. eCollection 2023. Front Neurol. 2023. PMID: 37181568 Free PMC article.
-
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimers Dement. 2025 Jan;21(1):e14338. doi: 10.1002/alz.14338. Epub 2025 Jan 8. Alzheimers Dement. 2025. PMID: 39776249 Free PMC article.
-
Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.Neurobiol Aging. 2020 Dec;96:137-147. doi: 10.1016/j.neurobiolaging.2020.08.003. Epub 2020 Aug 21. Neurobiol Aging. 2020. PMID: 33002767 Free PMC article.
-
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.Neurology. 2020 Dec 15;95(24):e3257-e3268. doi: 10.1212/WNL.0000000000010943. Epub 2020 Sep 28. Neurology. 2020. PMID: 32989106 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical